These results provide a basis for using EZH2 inhibitors [38-40] in combination with inducers of terminal B cell differentiation, such as IL-21 [41, 42] and genotoxic agents, for the treatment of GC-derived DLBCL and follicular lymphoma. Here, EZH2 is linked to diffuse large B-cell lymphoma.